Intercell Reports Phase II Study Results Of Its Vaccine Enhancement Patch For Pandemic Influenza
July 6, 2010 – 1:21 pmIntercell AG (VSE: ICLL) announced the results of a Phase II clinical trial of its investigational Vaccine Enhancement Patch (VEP) system for avian H5N1 influenza. In this development program, Intercell is working under a contract with the U.S. Department of Health and Human Services (HHS) to develop a dose-sparing approach with potential for a single dose immunization against pandemic influenza that combines a H5N1 vaccine with Intercell’s LT adjuvant patch…
Find more info about Intercell Reports Phase II Study Results Of Its Vaccine Enhancement Patch For Pandemic Influenza photos videos pictures. read more
Related Info :
Tags: Adjuvant, Avian Influenza, Clinical Trial, Department Of Health And Human, Department Of Health And Human Services, Enhancement, Enhancement Patch, H5n1 Influenza, H5n1 Vaccine, Health And Human Services, Hhs, Immunization, Influenza, Influenza Pictures, Intercell, Investigational Vaccine, Pandemic, Pandemic Influenza, Patch, Phase, Phase Ii, Reports, Results, Study, U S Department, U S Department Of Health And Human Services, vaccine, Vse
Sorry, comments for this entry are closed at this time.